Trial Profile

Experimental Study on the Safety, Tolerability, Pharmacokinetics and Efficacy of B002 in the Treatment of HER2-positive Recurrent or Metastatic Breast Cancer

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 27 Mar 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs B 002 (Primary)
Indications Advanced breast cancer; HER2 positive breast cancer
Focus Adverse reactions
Acronyms B002-101
Sponsors Shanghai Pharmaceuticals Holding

Most Recent Events

23 Mar 2023 Status changed from recruiting to completed.
13 Feb 2023 Planned primary completion date changed from 30 Dec 2022 to 28 Feb 2023.
20 Oct 2022 Planned End Date changed from 31 Dec 2022 to 31 Jul 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com